Latest Advances in Lung Cancer Research

Early detection of incidental lung nodules can lead to timely treatment and improved survival rates for lung cancer patients.

New hope for small cell lung cancer patients as the first patient receives Peluntamig in a clinical trial. This experimental drug targets specific cancer growth pathways.

New blood test using ctDNA methylation biomarkers shows promise for early lung cancer detection, potentially improving treatment outcomes for patients.

New drug shrinks HER2-mutant lung cancer tumors in 73% of patients, offering hope for improved treatment options.

Comprehensive review examining molecular mechanisms of cancer invasion and metastasis, identifying potential therapeutic targets for preventing cancer spread.

Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.

Final study results show selpercatinib achieves 83% response rate in treatment-naive RET fusion lung cancer patients with durable responses.

Increasing lung cancer cases in non-smokers highlight the need for research into causes and improved detection methods

UC Davis Health introduces cutting-edge CT imaging technology that detects smaller lung tumors with less radiation, improving early detection and treatment planning.

Obesity paradox in lung cancer: Study finds obesity associated with improved survival in NSCLC patients, particularly those with preserved skeletal muscle quality and quantity.

New study reveals higher lung cancer incidence in women under 65 than in men, with rates increasing among younger women despite declining smoking trends.

Expanding lung cancer screening to those aged 50-80 with 20 pack-year smoking history could increase eligibility by 87%, reducing disparities and saving lives.